×
Search

866-540-5505

Se Habla Espanol
Menu
Search

Our Blog

Home/Blog/Novartis Pays Over $642 Million to Settle FCA Allegations

Novartis Pays Over $642 Million to Settle FCA Allegations

On July 1, 2020, the Department of Justice (“DOJ”) announced that Novartis Pharmaceutical Corporation (“Novartis”), a New Jersey-based pharmaceutical company, agreed to pay over $642 million in separate to resolve alleged violation of the False Claims Act (“FCA”), 31 U.S.C. §§ 3729–3733. The settlement resolves allegations that Novartis made improperly payments to Medicare patients and prescribing physicians to promote Novartis’s drugs, Gilenya and Afinitor.

The FCA allows private citizens (known as whistleblowers or relators) to bring lawsuits on behalf of the Government against entities suspected of misusing Government funds. The Anti-Kickback Statute (“AKS”), 42 U.S.C. § 1320a–7b(b), is a criminal law that prohibits anyone from offering or paying, directly or indirectly, kickbacks (“anything of value”) to induce referrals of items or services covered by Medicare, Medicaid, and other federally funded programs. This prohibition covers both improper payments to providers and prescribing physicians and the improper payment of patients’ copay obligations.

Together, the FCA and AKS serve as cornerstones in safeguarding integrity within government programs, particularly in healthcare. The FCA acts as a broad net, while the AKS targets specific practices within healthcare. Violations of the AKS often trigger the FCA, creating a powerful dual enforcement mechanism. This underscores the importance of ethical conduct in government programs, particularly healthcare programs, where financial incentives can have far-reaching consequences.

Novartis, a giant in the pharmaceutical industry, tackles serious diseases with treatments fueled by hefty research and development spending. This translates to a wide range of drugs reaching millions worldwide, but also raises concerns about profit motives and potential ethical compromises. The Novartis drugs implicated in these settlements are Gilenya, used in the treatment of relapsing forms of multiple sclerosis, and Afinitor, used in the treatment of advanced renal cell carcinoma and progressive neuroendocrine tumors of pancreatic origin.

The $642 million dollar settlement encapsulates two different claims made against Novartis. The first settlement concludes accusations that the company skirted the law by using three foundations to secretly cover Medicare copays for patients taking Gilenya and Afinitor. Novartis reached a settlement of $51.25 million out of the total $642 million settlement to settle the allegations of improper copay payments for their medications.

The second settlement, initially brought by former Novartis sales representative and Plaintiff-Relator Oswald Bilotta, brings closure to an alleged scheme where Novartis offered doctors improper financial inducements known as kickbacks to prescribing the Novartis drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Tekamlo, Diovan, Diovan HCT, Exforge, and Exforge HCT. Novartis agreed to pay $591 million, plus $38.4 million in asset forfeiture, to resolve claims under the FCA and Civil Asset Forfeiture Statute related to alleged kickbacks to doctors for prescribing Novartis medications. Although the settlement does not give a true determination of liability, as is common with these types of cases, Novartis made extensive factual admissions and conceded to significant curbs on future speaker programs, including considerably lower spending allowances.

This settlement agreement concludes the litigation entitled United States ex rel. Bilotta v. Novartis Pharmaceuticals Corp., case number 11-cv-0071-PGG, brought in the U.S. District Court for the Southern District of New York.

The legal team at Miller Shah LLP has extensive experience representing whistleblower matters. If you have any questions regarding this subject or this post, please contact Bruce D. Parke (bdparke@millershah.com) or Alec Berin (ajberin@millershah.com). The firm can also be reached toll-free at (866) 540-5505.

Share Post:
facebooktwitterLinkedin

Categories

Archives

Contact
Miller Shah LLP

While this website provides general information, it does not constitute legal advice. The best way to get guidance on your specific legal issue is to contact a lawyer. To schedule a meeting with an attorney, please call 866-540-5505 or complete the intake form to email us.
Alec J. Berin - Associate

PA Philadelphia | 866-540-5505

Alfonso Vilaboa - Of Counsel

NJ Hoboken |

Anika S. Keuning - Project Analyst

CA San Diego | 866-540-5505

Anna D’Agostino - Associate

NY New York City | 866-540-5505

Betsy Ferling-Hitriz - Legal Assistant

CT Chester | 866-540-5505

Bruce D. Parke - Partners

PA Philadelphia | 866-540-5505

Caroline Soper - Project Analyst

NY New York City | 866-540-5505

Christopher A. Miller - Associate

PA Philadelphia | 866-540-5505

Deborah C. England - Of Counsel

CA San Francisco | 866-540-5505

Edward H. Glenn - Of Counsel

NY New York City | 866-540-5505

Edward M. Fitzgerald - Staff Attorney

CA Los Angeles | 866-540-5505

Elena M. DiBattista - Legal Assistant

FL Fort Lauderdale | 866-540-5505

Elise M. Wilson - Project Analyst

NY New York City | 866-540-5505

Eric L. Young - Of Counsel

PA Philadelphia | 866-540-5505

Finn M. Mutrux - Office Staff

CA Los Angeles | 866-540-5505

Gina S. Demetriades - Office Staff

CT Chester | 866-540-5505

Heidi A. Wendel - Of Counsel

NY New York City | 866-540-5505

James C. Shah - Partners

CA Los Angeles | 866-540-5505

James E. Miller - Partners

CT Chester | 866-540-5505

Jayne A. Goldstein - Partners

FL Fort Lauderdale | 866-540-5505

Jillian M. Boyce - Office Staff

CT Chester | 866-540-5505

Jocelyn McNamara - Project Analyst

NY New York City | 866-540-5505

Johanna C. Richter - Law Clerk

PA Philadelphia | 866-540-5505

John C. Roberts - Associate

PA Philadelphia | 866-540-5505

Jonathan Dilger - Office Staff

NY New York City | 866-540-5505

Julie M. Capito - Legal Assistant

CA San Francisco | 866-540-5505

Katie Edwards - Legal Assistant

PA Philadelphia | 866-540-5505

Kolin C. Tang - Partners

CA San Diego | 866-540-5505

Laurie Rubinow - Partners

CT Chester | 866-540-5505

Madison Gregg - Associate

NY New York City | 866-540-5505

Marialisa Samo - Legal Assistant

CA San Diego | 866-540-5505

Mark Xiao - Associate

NY New York City | 866-540-5505

Natalie Finkelman Bennett - Partners

PA Philadelphia | 866-540-5505

Nathan C. Zipperian - Partners

FL Fort Lauderdale | 866-540-5505

Nicholas Day - Of Counsel

NJ Hoboken | 866-540-5505

Nicholas K. Ono - Project Analyst

NY New York City | 866-540-5505

Raffaele Scalcione - Of Counsel

IT Milan | 866-540-5505

Reilly K. Powers - Project Analyst

PA Philadelphia | 866-540-5505

Robert W. Biela - Staff Attorney

PA Philadelphia | 866-540-5505

Ronald S. Kravitz - Of Counsel

CA San Francisco | 866-540-5505

Rrita Osmani - Project Analyst

CT Chester | 866-540-5505

Shuping Li - Project Analyst

NY New York City | 866-540-5505

Stephen T. Rutkowski - Law Clerk

CT Chester | 866-540-5505

Sue Moss - Legal Assistant

PA Philadelphia | 866-540-5505

Sydney D. Finlay - Associate

CA San Diego | 866-540-5505

Tina Moukoulis - Staff Attorney

PA Philadelphia | 866-540-5505